A recent study demonstrated that the RUNX1-RUNX1T1 can be targeted and disrupted utilizing a dual intron-targeting CRISPR-Cas9-mediated strategy elucidating this novel methodology’s potential in future treatment of AML t(8;21) patients [156]. Here, RUNX1 is linked to acute myeloid leukemia.